EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia

Rachel D Harris iD, Olga A Taylor, M Monica Gramatges, Amy E Hughes, Mark Zobeck iD, Sandi Pruitt, M Brooke Bernhardt iD, Ashley Chavana iD, Van Huynh, Kathleen Ludwig, Laura Klesse iD, Kenneth Heym und 13 weitere

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025

DOI: 10.1002/phar.4638 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Verfasst von Rachel D Harris und 24 weiteren Autor:innen. Beteiligte Einrichtung: Texas Children's Cancer and Hematology Centers, Houston, Texas, USA. Hauptthemen laut MEDLINE: Antimetabolites, Antineoplastic, Methotrexate, Neurotoxicity Syndromes, Pharmacogenomic Variants. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: St. Baldrick's Foundation, NCI NIH HHS, Cancer Prevention and Research Institute of Texas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Methotrexate is an important component of curative therapy in childhood acute lymphoblastic leukemia (ALL), but the role of genetic variation influencing methotrexate clearance and transport in toxicity susceptibility in children with ALL is not well established. Therefore, we evaluated the association between suspected methotrexate pharmacogenomic variants and methotrexate‐related neurotoxicity.

Methods

This study included children (aged 2–20 years) diagnosed with ALL (2005–2019) at six treatment centers in the southwest United States. Clinical information was abstracted from medical records. Suspected neurotoxic events occurring within 21 days of intravenous and/or intrathecal methotrexate delivered between the end of induction and start of maintenance therapy were independently reviewed by at least two pediatric oncologists. Germline DNA was genotyped and 97 methotrexate pharmacogenomic variants of interest with at least grade 3 evidence were identified using the Pharmacogenomics Knowledge Base. Associations between variants and neurotoxicity were assessed by logistic regression. Data were randomly split (80/20) and random forest was constructed to estimate the ability of the variants to correctly classify neurotoxicity.

Results

Of the 763 patients included in the study, 8.2% ( n = 63) developed methotrexate‐associated neurotoxicity. In logistic models, none of the 97 available pharmacogenomic variants reached adjusted statistical significance. However, two variants, rs17222723 (odds ratio [OR] = 2.83 [ref. = T allele], 95% confidence interval [CI]: 1.20–6.15) in ABCC2 and rs1045642 (OR = 0.66 [ref. = minor A allele], 95% CI: 0.44–0.98) in ABCB1 , were nominally associated ( p ‐value < 0.05) with neurotoxicity susceptibility. The addition of pharmacogenomic variants did not improve the predictive performance of random forest model (AUC = 0.73) compared to clinical information alone (AUC = 0.74).

Conclusion

Overall, our results suggest that associations between neurotoxicity susceptibility and methotrexate pharmacogenomic variants are generally modest and these variants do not significantly improve neurotoxicity risk stratification among children with ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antimetabolites, AntineoplasticMethotrexateNeurotoxicity SyndromesPharmacogenomic VariantsPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolFemaleHumansMaleYoung AdultMultidrug Resistance-Associated Protein 2PharmacogeneticsRetrospective StudiesATP Binding Cassette Transporter, Subfamily B

Stichwörter der Autor:innen

acute lymphoblastic leukemiaepidemiologymethotrexateneurotoxicityoncologypediatricspharmacoepidemiologypharmacogenomics

Substanzen

ABCB1 protein, humanABCC2 protein, humanAntimetabolites, AntineoplasticMethotrexateMultidrug Resistance-Associated Protein 2ATP Binding Cassette Transporter, Subfamily B

Autor:innen und Institutionen

  • Texas Children's Cancer and Hematology Centers, Houston, Texas, USA.
  • Division of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Pediatrics, Center for Epidemiology and Population Health, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Epidemiology, Human Genetics, and Environmental Science, University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

ORCID-Profile: Rachel D Harris, Mark Zobeck, M Brooke Bernhardt, Ashley Chavana, Laura Klesse, Austin L Brown

Förderung

  • St. Baldrick's Foundation
  • NCI NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • NIH HHS
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Harris, R. D., Taylor, O. A., Gramatges, M. M., Hughes, A. E., Zobeck, M., Pruitt, S., Bernhardt, M. B., Chavana, A., Huynh, V., Ludwig, K., Klesse, L., Heym, K., Griffin, T., Erana, R., Bernini, J. C., Choi, A., Ohno, Y., Richard, M. A., Morrison, A. C., …, & Brown, A. L. (2025). Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.4638

Vancouver

Harris RD, Taylor OA, Gramatges MM, Hughes AE, Zobeck M, Pruitt S, et al. Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.4638

BibTeX
@article{Harris2025,
  author = {Harris, Rachel D and Taylor, Olga A and Gramatges, M Monica and Hughes, Amy E and Zobeck, Mark and Pruitt, Sandi and Bernhardt, M Brooke and Chavana, Ashley and Huynh, Van and Ludwig, Kathleen and Klesse, Laura and Heym, Kenneth and Griffin, Timothy and Erana, Rodrigo and Bernini, Juan Carlos and Choi, Ashley and Ohno, Yuu and Richard, Melissa A and Morrison, Alanna C and Chen, Han and Yu, Bing and Lupo, Philip J and Rabin, Karen and Scheurer, Michael E and Brown, Austin L},
  title = {Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  doi = {10.1002/phar.4638}
}
Kostenlos starten →